StreetAlpha.app
Home › Stocks › IVA

Inventiva S.A. (IVA)

Healthcare
$3.22
▼ −3.01%
LAST CLOSE · NOV 17

Inventiva is a French biopharmaceutical company developing lanifibranor, an oral treatment for the liver disease MASH. It last closed at $3.22 on Nov 17, down 3.01% on the day. IVA last reported earnings on Fri, Sep 25, 2026. The average 12-month price target from 4 analysts is $16.75 (+420.2% from the last close), with a high of $21.00 and a low of $14.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $400K, the largest $400K.

AI Auto Pilots
Is IVA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
EUR 13.6M
−12.8% vs a year ago
Net income
−EUR 311.1M
−2285.4% margin
Operating margin
−795.3%
−EUR 108.2M operating income
Balance sheet
Cash & equivalents
EUR 122.1M
At Jun 30
Shareholder equity
−EUR 8.9M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2020: EUR 372KEUR 372KFY2020FY2021: EUR 4.2MEUR 4.2MFY2021FY2022: EUR 12.2MEUR 12.2MFY2022FY2023: EUR 17.5MEUR 17.5MFY2023FY2024: EUR 9.2MEUR 9.2MFY2024

From IVA's SEC filings, latest 20-F for the period ending Jun 30, 2025 (filed Apr 8). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Last report
Sep 25
2026 · After the close (AMC)
Reported EPS
$0.00
vs -$0.34 est. · beat
Year-ago EPS
-$1.62
Same quarter last year
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on IVA in the past 90 days
Average 12-month target
$16.75
▲ 420.2% upside

Based on 4 analysts who set a price target on IVA in the past 90 days. The average target is $16.75, with a high of $21.00 and a low of $14.00, compared with the last close of $3.22.

Low $14.00Avg $16.75High $21.00
Blue marker: last close $3.22
Highest target$21.00
Average target$16.75
Lowest target$14.00
Latest rating changes
HC Wainwright & Co.Maintained
Nov 5Buy$14
Truist SecuritiesMaintained
Oct 2Buy$18
Canaccord GenuityMaintained
Sep 29Buy$21
GuggenheimMaintained
Sep 15Buy$14
HC Wainwright & Co.Maintained
Aug 16Buy$13
DateFirmActionRatingPrice target
Nov 5HC Wainwright & Co.MaintainedBuy$14
Oct 2Truist SecuritiesMaintainedBuy$18
Sep 29Canaccord GenuityMaintainedBuy$21
Sep 15GuggenheimMaintainedBuy$14
Aug 16HC Wainwright & Co.MaintainedBuy$13
Loading…

Technical Analysis

IVA · as of the Nov 17 close · updated after every close
Downtrend

The stock is 15% below its 20 day and 11% below its 50 day average. It is 46% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38). The nearest support is the Pivot S1 at $3.11, and the nearest resistance the Pivot R1 at $3.34.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 8.5%/day
Key levels
$7.2952 week high+126.4%
$4.71200 day average+46.3%
$4.05100 day average+25.8%
$3.7220 day average+15.5%
$3.72Swing high (Jun 23)+15.5%
$3.5850 day average+11.2%
$3.34Pivot R1+3.7%
$3.22Pivot+0.0%
$3.22Last close
$3.11Pivot S1−3.4%
$3.11Swing low (Sep 24)−3.4%
$2.8252 week low−12.4%
Indicators
RSI (14)38.38Weak, oversold below 30Neutral
MACD0.00Below its signal lineBearish
Stochastic9.8Near the bottom of its rangeOversold
ADX (14)27.1Trending down
Williams %R-90.5Oversold below −80, overbought above −20Oversold
CCI (20)-251.1Oversold below −100, overbought above 100Oversold
Rate of change−20.1%Change over 10 sessionsBearish
ATR (14)$0.28Typical daily range, 8.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IVA

What happened before

See how IVA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IVA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IVA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IVA in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$400K
Largest print
$400K
Loading…

IVA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲52 buying vs 39 selling
  • ▲Shares held by funds +7.9%
  • ▲Funds holding +10
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding9888+11.4%
In funds' top 10440.0%
Held by funds–––
New / increased25 / 2731 / 36−22.4%
Reduced / sold out24 / 157 / 7+178.6%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IVA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IVA is in one of them and how their past IVA trades turned out.

IVA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IVA in an article yet. Here's the latest on the wider market.

About Inventiva S.A.

Inventiva is a biopharmaceutical company based in Daix, France. It focuses on developing treatments for MASH, a progressive chronic liver disease marked by fat buildup, inflammation and scarring in the liver. Its main candidate, lanifibranor, is an orally available small molecule that is being studied in patients with MASH. The company aims to offer the treatment to these patients if regulators approve it.

Headquarters
Daix, France